The effect of ciprofloxacin pretreatment on the pharmacokinetics and metabolism of antipyrine in male rats was studied. The animals received oral antipyrine (20 mg/kg of body weight) with and without ciprofloxacin pretreatment (40 mg/kg orally once a day for 8 days). The total plasma clearance of antipyrine was decreased from 0.130 0.007 to 0.090 0.005 liter/h (mean standard error of the mean) (P < 0.01) by ciprofioxacin, while the half-life at , (elimination) phase and the area under the concentration-time curve for antipyrine were increased from 1.90 0.22 to 2.83 0.29 h (P < 0.05) and from 43.25 ± 3.35 to 52.41 ± 2.31 mg-h/liter (P < 0.05), respectively. The urinary excretions of norantipyrine, 4-hydroxyantipyrine, and 3-hydroxymethylantipyrine decreased by 73, 43, and 54%, respectively (P < 0.001), in the 96 h after ciprofloxacin treatment. In addition, the rate constants for formation of each of these metabolites were significantly decreased, by an average of approximately 75%. These results suggest that ciprofloxacin is capable of inhibiting oxidative metabolism. This finding could be of clinical significance for drugs that are highly dependent of metabolic pathways, such as those inhibited in this study.
Ciprofloxacin is a fluorinated quinolone which has a broad spectrum of antibacterial activity and widespread distribution to most tissues and body fluids. Thus, it is likely that ciprofloxacin should have potential therapeutic application in many types of infection (3) .
Recent studies have demonstrated that ciprofloxacin, as well as structurally related compounds, has the ability to increase theophylline and caffeine levels in blood (2, 7-9, 11-13, 15, 19, 21, 23) . The mechanism of this interaction has been suggested to be inhibition of cytochrome P-450-mediated xanthine derivative metabolism by fluorinated quinolones or their 4-oxo derivatives on the 3 position of the piperazine ring (24) .
Potentially significant interactions could occur among fluorinated quinolones and other drugs which are metabolized by hepatic cytochrome P-450 enzymes. This could be of clinical significance because ciprofloxacin and other new quinolones are usually used in combination with other therapeutic agents. The purpose of this investigation was to examine the effect of ciprofloxacin pretreatment on the pharmacokinetics and metabolism of the classical oxidative substrate antipyrine. MATERIALS All other chemicals used were obtained from the usual commercial sources and were routinely of the highest grade available. Antipyrine assay. Antipyrine in plasma and antipyrine and its metabolites 4-hydroxyantipyrine, norantipyrine, and 3-hydroxymethylantipyrine in urine were measured in our laboratory by a high-pressure liquid chromatographic method previously described (5). Plasma samples (1 ml) were mixed with 0.1 ml of internal standard solution, 0.1 ml of 2 N sodium hydroxide, and 5 ml of dichloromethanepentane (1:1). Urine samples (1 ml) were mixed with 0.4 ml of internal standard solution, 3 ml of 0.1 M acetate buffer (pH 4.5), 4 mg of sodium metabisulfite, and 40 mg of 3-glucuronidase-sulfatase. After incubation for 3 h at 37°C, samples (1 ml) (equivalent to 0.25 ml of urine) were mixed with 200 mg of sodium sulfate, 0.1 ml of 4 N sodium hydroxide, and 10 ml of dichloromethane to determine antipyrine and 3-hydroxymethylantipyrine in the urine. In addition, samples (1 ml) (equivalent to 0.25 ml of urine) were mixed with 5 ml of dichloromethane-pentane (30:70) to determine 4-hydroxyantipyrine and norantipyrine in urine. The internal standard solution was prepared by dissolving phenacetin in distilled water (0.4 mg/ml). After extraction, the upper organic layer was evaporated to dryness at 40°C under a gentle stream of nitrogen. The resulting residue was dissolved in 0.1 ml of the eluting mobile phase. Twenty microliters of this solution was injected into the high-performance liquid chromatographic system (model LC-6A with UV spectrophotometric detector model SPD-6A and data processor model Chromatopac CR-6A [all from Shimadzu]) equipped with a Lichrosorb RP-2 column (particle size, 5 jim; 4 by 150 mm; Merck). The eluting mobile phase was a solution of 5% acetonitrile in 0.05 M phosphate buffer (pH 6.5). Detection took place at a wavelength of 244 nm. For plasma, standard curves were linear from 0.01 to 10 ,ug of antipyrine per ml, with intra-and interday coefficients of variation below 3.6%. The detection limit was 0.01 jig/ml.
For urine, standard curves were linear from 0.1 to 20 pLg/ml for antipyrine and from 0.1 to 40 ,ug/ml for its metabolites. The intra-and interday coefficients of variation were less than 5.6%. The detection limits were 0.1 ,ug/ml for antipyrine and its metabolites. Ciprofloxacin did not interfere with the assay of antipyrine or its metabolites.
Data analysis. The antipyrine concentrations in plasma measured after an oral dose were fitted to a two-compartment open model for kinetic analysis. Pharmacokinetic parameters were obtained by using an extended-leastsquares nonlinear regression program, ELSFIT (17) . The plasma curves of antipyrine after oral administration were fitted to the following exponential equation: C = A1e`' + A2e-'-A3e-Ka', where C is the concentration of antipyrine in plasma; A1, A2, and A3 are mathematical coefficients; a is the hybrid rate constant for the distribution phase; a is the hybrid rate constant for the terminal (elimination) phase; Ka is the first-order absorption rate constant; and t is time. This equation was chosen by using the statistical method called the minimum Akaike Information Criterion estimation (25) . Formation rate constants for each of the three major metabolites of antipyrine measured in urine were calculated by multiplying ,B by the fraction of the administered dose excreted as metabolite (4).
Student's t test was used to evaluate statistical differences in antipyrine pharmacokinetics and metabolite excretion. Differences were considered significant only if P was <0.05. Values are expressed as the mean + standard error of the mean (SEM).
RESULTS
The profiles of antipyrine concentrations versus time are illustrated in Table 1 and Fig. 1 . The kinetics of antipyrine changed significantly after ciprofloxacin treatment. Table 2 summarizes the pharmacokinetic data obtained. Rats pretreated with ciprofloxacin showed a markedly slower plasma elimination of antipyrine than the control animals. Changes in both plasma clearance and half-life at ,B phase were statistically significant. No significant differences were observed in volumes of distribution during the elimination phase. The area under the curve in ciprofloxacin-treated rats was also significantly higher than in control animals.
The urinary recovery of antipyrine, norantipyrine, 4-hydroxyantipyrine, and 3-hydroxymethylantipyrine was found to account for 91.5% of the dose when antipyrine was administered before ciprofloxacin treatment but only 38.8% when it was given after ciprofloxacin treatment (P < 0.001). As illustrated in Fig. 2 , significant changes were found in the excretion of norantipyrine (decreased 73%), 4-hydroxyantipyrine (decreased 43%), and 3-hydroxymethylantipyrine (decreased 54%). The formation rate constants for these metabolites both before and after ciprofloxacin pretreatment are shown in Table 3 . Statistically significant decreases were found for all the measured metabolites.
DISCUSSION
In this investigation, the pharmacokinetic and metabolic properties of antipyrine were studied under control conditions and following pretreatment with ciprofloxacin. Ciprofloxacin pretreatment was found to consistently and significantly decrease the total plasma clearance and prolong the half-life of antipyrine without affecting the volume of distri- bution during the elimination phase. Although these changes in clearance and half-life were statistically significant, the magnitude of the observed changes was small (total plasma clearance was decreased by 28.5%). One might predict on the basis of pharmacokinetic data alone that the effects of ciprofloxacin on oxidative metabolism would be unlikely to be of clinical significance. However, examination of the urinary excretion data suggests an effect of greater magnitude.
Ciprofloxacin was found to significantly decrease the fraction of the administered dose recovered as antipyrine and measured metabolites, as well as the recovery of each individual metabolite. Our finding of 91.5% urinary recovery of antipyrine and its three major metabolites under control conditions in rats is different from the results of other investigators, who have recovered 64.3% (18), 44% (1), and 61.1% (6) of antipyrine doses as these products in humans. However, in our experiments all urine excreted for 96 h following the antipyrine dose was collected, whereas previously reported data were obtained with urine excreted for 48 h. The decrease in metabolite recovery after ciprofloxacin treatment could be related not only to impaired formation but also to a decrease in antipyrine bioavailability. However, the latter appears unlikely since concentrations of antipyrine in plasma in the first hours following administration were nearly identical in both cases.
The precise fate of the remaining percentage of a dose of antipyrine is not known at this time. However, this investigation showed that the elimination of antipyrine through measured metabolic pathways is affected by ciprofloxacin administration. The formation rate constants representing the measured metabolic pathways were changed (Table 3) . A decrease in formation rate constants for the three major metabolites of antipyrine (averaging 75%) was observed.
The results of this investigation clearly show that ciprofloxacin is capable of inhibiting the oxidative metabolism of antipyrine. Previously, several reports have also suggested that the elimination half-life of antipyrine was moderately prolonged by ciprofloxacin (10, 20) . However, data concerning the effect of ciprofloxacin on the individual pathways of antipyrine metabolism have not been reported. The magnitude of impairment in the formation rate constants of the three major metabolites is greater than the one observed with cimetidine (18) . For drugs which are highly dependent on pathways such as these for elimination, coadministration of ciprofloxacin could result in a clinically significant impairment in clearance. Reports of patients who experienced increased concentrations of theophylline in plasma following the initiation of ciprofloxacin therapy (11, 13, 14, 18, 22) support this possibility. An in vitro effect of ciprofloxacin on theophylline metabolism in human liver microsomes (16) also correlates with this clinical interaction. Our present study concerning the effect of chronic ciprofloxacin pretreat- EFFECT OF CIPROFLOXACIN ON ANTIPYRINE PHARMACOKINETICS ment on oxidative metabolism will be useful not only in assessing the clinical implications but also in providing insight into the mechanism of enzyme inhibition by this drug.
